The Zhitong Finance App learned that BlossomHill Therapeutics is a biotechnology company whose pipeline has advanced to the second phase of clinical trials, focusing on developing small-molecule anti-cancer therapies. The company submitted a prospectus to the US Securities and Exchange Commission (SEC) on Friday to raise up to $100 million through an initial public offering (IPO).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.